Hydrochlorothiazide 12.5/25/50 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Peripheral Edema/Hypertension (Diuretics)

• Furosemide
• Furosemide 20/40/80 mg tabs

About Hydrochlorothiazide 12.5/25/50 mg tabs

Hydrochlorothiazide, often referred to as HCTZ, is a widely prescribed medication crucial for managing high blood pressure and fluid retention. It's a cornerstone in cardiovascular health, helping millions lead healthier lives. At TheDrugClub, we believe essential medications should be accessible and affordable. Discover how you can get your hydrochlorothiazide for $0 co-pay, complete with convenient home delivery.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Hydrochlorothiazide 12.5/25/50 mg tabs is approved for (FDA label)

Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide has also been found useful in edema due to various forms of renal dysfunction such as the nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Hydrochlorothiazide 12.5/25/50 mg tabs (FDA label)

The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity. Body As A Whole : Weakness. Cardiovascular : Hypotension including orthostatic hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs). Digestive : Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting. sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia. Hematologic : Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia. Hypersensitivity : Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura. Metabolic: Electrolyte imbalance {see PRECAUTIONS ), hyperglycemia, glycosuria, hyperuricemia. Musculoskeletal : Muscle spasm. Nervous System/Psychiatric: Vertigo, paresthesias, dizziness, headache, restlessness.

Source: FDA prescribing information (DailyMed). Set ID: f20fd735-30c7-4f89-8ceb-b6186646eea6. SPL document ID: 5a09bf40-36b4-d1eb-e063-6394a90a4ee0. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Hydrochlorothiazide 12.5/25/50 mg tabs (FDA label)

Anuria. Hypersensitivity to this product or to other sulfonamide-derived drugs

Source: FDA prescribing information (DailyMed). Set ID: f20fd735-30c7-4f89-8ceb-b6186646eea6. SPL document ID: 5a09bf40-36b4-d1eb-e063-6394a90a4ee0. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Hydrochlorothiazide 12.5/25/50 mg tabs (FDA label)

When given concurrently the following drugs may interact with thiazide diuretics. Alcohol, Barbiturates, or Narcotics -potentiation of orthostatic hypotension may occur. Antidiabetic Drugs· (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. Other Antihypertensive Drugs - additive effect or potentiation. Cholestyramine and Colestipol Resins - Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of cholestyramine and colestipol resins bind the hydrochlorothiazide and reduce its absorption in the gastrointestinal tract by up to 85 and 43 percent, respectively. Corticosteroids, ACTH - intensified electrolyte depletion, particularly hypokalemia. Pressor Amines (e.g., Norepinephrine) - possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal Muscle Relaxants, Nondepolarizing (e.g., Tubocurarine) - possible increased responsiveness to the muscle relaxant. Lithium - generally should not be given with diuretics.

Source: FDA prescribing information (DailyMed). Set ID: f20fd735-30c7-4f89-8ceb-b6186646eea6. SPL document ID: 5a09bf40-36b4-d1eb-e063-6394a90a4ee0. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.